XOMA Royalty Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

28.19

Bid

16.63

Ask

30.03

Volume

63,166

28.00 Day's Range 29.70

13.48 52 Week Range 30.36

Market Cap

329.949M

Previous Close

29.85

Open

29.68

Last Trade

27.63

Last Trade Time

Financial Volume

$ 1,860,138

VWAP

29.4484

Average Volume (3m)

21,809

Shares Outstanding

11,704,467

Dividend Yield

PE Ratio

-8.10

Earnings Per Share (EPS)

-3.49

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA Royalty was $29.85. Over the last year, XOMA Royalty shares have traded in a share price range of $ 13.48 to $ 30.36.

XOMA Royalty currently has 11,704,467 shares outstanding. The market capitalization of XOMA Royalty is $349.38 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -8.10.

XOMA Royalty to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at...

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the...

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...

Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.42	1.51242347857	27.77	29.9	27.5701	17287	28.98231437	CS
4	-0.73	-2.52420470263	28.92	29.9	25.95	22022	28.36422119	CS
12	4.78	20.4186245194	23.41	30.36	22.7	21809	27.52101649	CS
26	3.29	13.2128514056	24.9	30.36	21.27	17568	26.35369877	CS
52	11.86	72.6270667483	16.33	30.36	13.48	21933	21.88858438	CS
156	3.41	13.7610976594	24.78	32.085	13.48	29118	20.68687271	CS
260	7.69	37.512195122	20.5	46.32	13.48	35951	24.1936098	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BNZIBanzai International Inc	$ 5.645 (96.01%)	61.39M
ZJYLJin Medical International Ltd	$ 3.975 (50.00%)	1.24M
ANEBAnebulo Pharmaceuticals Inc	$ 2.9001 (39.43%)	78.85k
XPONExpion360 Inc	$ 0.081 (39.18%)	1.46B
AENTAlliance Entertainment Holding Corporation	$ 2.74 (34.31%)	4.23M
GSIWGarden Stage Ltd	$ 1.34 (-82.89%)	26.44M
CRBPCorbus Pharmaceuticals Holdings Inc	$ 19.51 (-62.26%)	12.29M
LGCBLinkage Global Inc	$ 0.4183 (-57.70%)	2.16M
BFIBurgerFi International Inc	$ 0.0855 (-42.27%)	15.05M
SKYESkye Bioscience Inc	$ 3.17 (-42.26%)	5.14M
XPONExpion360 Inc	$ 0.081 (39.18%)	1.46B
NVDANVIDIA Corporation	$ 116.00 (-1.59%)	377.84M
AAPLApple Inc	$ 228.20 (-0.29%)	320.78M
INTCIntel Corporation	$ 21.84 (3.31%)	261.68M
VERBVerb Technology Company Inc	$ 0.0742 (33.45%)	178.65M